drugset / Trial / NCT00193505
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2003-10
- Primary completion
- 2005-08
- Completion
- 2005-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 90Y Zevalin | Monoclonal antibody | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Etoposide | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |